ROBBIN OLIVER: Open Payments
NPI 1174870786 · VINTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$950 in 50 payments from 13 companies in 2025. Trend: 2023 $391 · 2024 $1,100 · 2025 $950
Food & beverage: $950
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $266 |
| AstraZeneca Pharmaceuticals LP | 6 | $107 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Lilly USA, LLC | 6 | $97 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $69 |
| Novo Nordisk Inc | 3 | $62 |
| GlaxoSmithKline, LLC. | 3 | $60 |
| Amgen Inc. | 3 | $46 |
| Exact Sciences Corporation | 2 | $38 |
| Ascendis Pharma Endocrinology Inc | 2 | $33 |
Products named: VRAYLAR, REXULTI, UBRELVY, MOUNJARO, XIFAXAN, TRELEGY ELLIPTA, BREZTRI, QULIPTA.
Industry payments across VA — which companies pay providers there.
